- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease ; volume:38 ; number:1 ; day:13 ; month:11 ; year:2023 ; pages:5-22 ; date:1.2024
BioDrugs ; 38, Heft 1 (13.11.2023), 5-22, 1.2024
- Creator
-
Cummings, Jeffrey
Osse, Amanda M. Leisgang
Cammann, Davis
Powell, Jayde
Chen, Jingchun
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40259-023-00633-2
- URN
-
urn:nbn:de:101:1-2024032721020156216725
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cummings, Jeffrey
- Osse, Amanda M. Leisgang
- Cammann, Davis
- Powell, Jayde
- Chen, Jingchun
- SpringerLink (Online service)
Other Objects (12)
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease
Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease
Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer’s disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness
The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
Development and characterization of novel anti-acetylated tau monoclonal antibodies to probe pathogenic tau species in Alzheimer’s disease
Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
Anti-Amyloid Therapies for Alzheimer’s Disease: An Alzheimer Europe Position Paper and Call to Action
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease
Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease
Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer’s disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness
The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
Development and characterization of novel anti-acetylated tau monoclonal antibodies to probe pathogenic tau species in Alzheimer’s disease
Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
Anti-Amyloid Therapies for Alzheimer’s Disease: An Alzheimer Europe Position Paper and Call to Action
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease
Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease
Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer’s disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness
The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
Development and characterization of novel anti-acetylated tau monoclonal antibodies to probe pathogenic tau species in Alzheimer’s disease
Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
Anti-Amyloid Therapies for Alzheimer’s Disease: An Alzheimer Europe Position Paper and Call to Action